DESCRIZIONE PROGETTO:
A wide variability was observed among FH patients, only partially due to the different genetic status (no variant, HeFH or HoFH) and clinical management of FH patients is notably affected by this extreme phenotypic variability, mainly by the variable susceptibility to CVD, and the low response to classical statin therapy or innovative therapies.
This joint project is aimed at the application of a multi-omic approach for the identification of innovative markers useful for the clinical management of FH patients. The improvement of knowledge of FH molecular bases would improve the diagnosis, also identifying additional therapeutic targets. In addition, it would also benefit the identification of factors related with the phenotype variability and with responsiveness to therapy, helping the FH patient management.
Coordinatore e personale ICB coinvolto:
Coordinatore per ICB: Dr Adele Cutignano (Co-PI), Dr Marco Andolfi (research fellow)
Ente capofila:
University of Naples “Federico II”
Enti partecipanti:
Consiglio Nazionale delle Ricerche
UNINA team:
Prof. Giuliana Fortunato (coordinatrice), Dr Gabriella Iannuzzo, Dr Ilenia Lorenza Calcaterra, Dr Martina Ferrandino (research fellow), Dr Maria Donata di Taranto (collaborator)
Altri dettagli finanziamento:
PRIN 2022 – Prot. 2022572TTW Funded by European Union – NEXT GENERATIONEU – PNRR M4/C2/1.1
Data inizio progetto: 28 settembre 2023
Data fine progetto: 27 settembre 2025
